Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: testing Dapagliflozin 10mg Tab for Myocardial Infarction

This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.

Official registry: https://clinicaltrials.gov/study/NCT06009874 · Mohammad Hussien Tantawy Soliman · enrollment listed as 80

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Dapagliflozin 10mg Tab, or Placebo. The registry lists allocation as randomized. This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.

They plan to enroll about 80 people at Shibīn al Kawm. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Clinical Investigation of Cardioprotective Effect of Early Administration of Sodium-glucose Cotransport-2 Inhibitors in Patients With Acute Myocardial Infarction

Interventions: Dapagliflozin 10mg Tab, Placebo

Primary outcome (registry wording): difference in infarct size

Who it is for (from inclusion criteria)

  • Ages 18 Years to 80 Years
  • Patients with ST-elevation myocardial infarction (STEMI)
  • STEMI was defined according to the Fourth Universal Definition of AMI
  • 18 - 80 years of age
  • Diabetics or non-diabetics
  • eGFR \> 45 ml/min/1.73m2
  • Blood pressure before first drug dosing \>110/70 mmHg

Public study contact (from the registry)

Mohammad Soliman

+201003474565

dr.mhtantawy@gmail.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

FAQ about this NCT record

Is NCT06009874 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06009874?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06009874?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary